Filing Details

Accession Number:
0001493152-24-000115
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-02 17:00:22
Reporting Period:
2023-12-28
Accepted Time:
2024-01-02 17:00:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1603207 Notable Labs Ltd. NTBL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776703 Fr Capital Holdings, L.p. 2400 Market Street,
Suite 237
Philadelphia PA 19103
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value Nis 0.35 Each Disposition 2023-12-28 21,500 $2.01 936,489 No 4 S Indirect See Footnote
Ordinary Shares, Par Value Nis 0.35 Each Disposition 2023-12-29 6,000 $1.83 930,489 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. FR Capital Holdings, L.P. (the "Reporting Person") is the investment manager to First Round Capital V, LP, a Delaware limited partnership ("FRCV"), and First Round Capital VIII-F, LP, a Delaware limited partnership ("FRCVIIIF"). Josh Kopelman and William Trenchard are the managing members of the Reporting Person. As of January 2, 2024, FRCV held 381,971 ordinary shares, par value NIS 0.35 each ("Ordinary Shares") of Notable Labs, Ltd. and FRCVIIIF held 549,985 Ordinary Shares. The Reporting Person's and Messrs. Kopelman and Trenchard's beneficial ownership is limited to their pecuniary interest, if any, in such securities.
  2. On December 28, 2023, FRCV sold 7,977 Ordinary Shares and FRCVIIIF sold 13,523 Ordinary shares, each at a weighted average price of $2.0068 per share. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. On December 29, 2023, FRCV sold 2,224 Ordinary Shares and FRCVIIIF sold 3,776 Ordinary shares, each at a weighted average price of $1.8316 per share. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.8601, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.